The study provided the new mechanistic evidence about TET3/miR-145/HK2 pathway in the anti-Warburg effect of berberine, providing evidence for berberine to become a candidate drug for clinical treatment of ovarian cancer. This evidence concerns the gene TET3 and ovarian carcinoma.